* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Download Encapsulation Services
SNARE (protein) wikipedia , lookup
Organ-on-a-chip wikipedia , lookup
Mechanosensitive channels wikipedia , lookup
Cell encapsulation wikipedia , lookup
List of types of proteins wikipedia , lookup
Implicit solvation wikipedia , lookup
Cell membrane wikipedia , lookup
Theories of general anaesthetic action wikipedia , lookup
Endomembrane system wikipedia , lookup
Provider of Global Contract Research Services Accelerating Preclinical Research, Drug Discovery & Therapeutics Services > Liposome Encapsulation Liposomes are bilayer (double-layer), liquid-filled bubbles made from phospholipids. Over 50 years ago, researchers discovered that these spheres could be filled with therapeutic agents and used to protect and deliver these agents into the body and even into specific cells of the body. The therapeutic value and greatly increased delivery of liposomeencapsulated drugs and nutrients. Altogen Labs • 11200 Manchaca Road • Suite 203 • Austin • TX • 78748 • USA [email protected] • (512) 433-6177 Services > Liposome Encapsulation Lipids, Phospholipids and Liposomes Lipids are a group of naturally occurring molecules that include fats, waxes, sterols, fat-soluble vitamins. The main biological functions of lipids include storing energy, signaling, and acting as structural components of cell membranes. Phospholipids are a class of lipids that are a major component of all cell membranes as they can form lipid bilayers. The structure of the phospholipid molecule generally consists of hydrophobic tails and a hydrophilic head. A liposome is a spherical vesicle having at least one lipid bilayer. The liposome can be used as a vehicle for administration of nutrients and pharmaceutical drugs. Liposomes can be prepared by disrupting biological membrane. Altogen Labs • 11200 Manchaca Road • Suite 203 • Austin • TX • 78748 • USA [email protected] • (512) 433-6177 Services > Liposome Encapsulation Liposomal formulations Since the first liposomal pharmaceutical product, Doxil, was approved in 1995 there are now several successful liposomal formulations. Most of them have to be administrated intravenously due to the degradation of lipids in the gastrointestinal tract. However, some recent formulations such as Arikace can be subcutaneously injected or inhaled as aerosols. Apart from a broadened range of drugs being investigated for liposomal formulations, new strategies such as environmental sensitivity and combination therapy have been applied to the development process to achieve better efficacy. Moreover, liposomes could be successfully applied to areas other than cancer therapy, such as vaccines. The next slide shows a table of clinically approved liposomal formulations. Altogen Labs • 11200 Manchaca Road • Suite 203 • Austin • TX • 78748 • USA [email protected] • (512) 433-6177 Services > Liposome Encapsulation Clinically Approved Liposomal Drugs Altogen Labs • 11200 Manchaca Road • Suite 203 • Austin • TX • 78748 • USA [email protected] • (512) 433-6177 Provider of Global Contract Research Services Accelerating Preclinical Research, Drug Discovery & Therapeutics Services > Liposome Encapsulation Altogen Labs offers encapsulation of any charged Standard formulations molecuIe such as mRNA, siRNA, shRNA, including all of the microRNA, plasmid DNA, protein The encapsulated molecule can be transformed into either one of several standard liposome formulations such as PC : Cholesterol and DSPC : Cationic Lipid : PEGylated Lipoid : Cholesterol or a custom liposome formulation This can be done in vitro or in vivo formulations listed in previous table Custom formulation Developing formulation methods Encapsulation of the compound of interest into liposomal formulation Altogen Labs • 11200 Manchaca Road • Suite 203 • Austin • TX • 78748 • USA [email protected] • (512) 433-6177 Services > Liposome Encapsulation Benefits and Applications Due to their unique properties, including low cytotoxicity, good biocompatibility and biodegradability, liposomes possess wide applications in different fields including gene and drug delivery, food and nutrition industries and cosmetic industries. Recently, a number of methods have been developed in order to modify the liposome structure and improve their stability as well as establishing high concentrations of bioactives in the target cells and cellular compartments in order to gain maximum therapeutic efficiency. Active targeting can be achieved via appropriately engineered modifications to the liposomal structure. For active targeting of liposomes, thermo-labile, pH-sensitive, photo-sensitive and antibody coated vesicles, have been designed. Through passive targeting, the bioactive-carrier complex reaches its destination based on the physicochemical properties of bioactive carrier complexes and does not require utilization of any targeting strategy. Services > Liposome Encapsulation Mechanism A liposome has an aqueous solution core surrounded by a hydrophobic membrane, in the form of a lipid bilayer. Hydrophilic solutes dissolved in the core cannot readily pass through the bilayer. Hydrophobic chemicals associate with the bilayer. A liposome can be hence loaded with hydrophobic and/or and hydrophilic molecules. To deliver the molecules to a site of action, the lipid bilayer can fuse with other bilayers such as the cell membrane, thus delivering the liposome contents. Useful liposomes rarely form spontaneously. They typically form after supplying enough energy to a dispersion of (phospho)lipids in a polar solvent, such as water, to break down multilamellar aggregates into oligoor unilamellar bilayer vesicles. Altogen Labs • 11200 Manchaca Road • Suite 203 • Austin • TX • 78748 • USA [email protected] • (512) 433-6177 Services > Liposome Encapsulation Mechanism By preparing liposomes in a solution of DNA or drugs (which would normally be unable to diffuse through the membrane) they can be (indiscriminately) delivered past the lipid bilayer, but are then typically distributed non-homogeneously. For drug delivery, liposomes that contain low (or high) pH can be constructed such that dissolved aqueous drugs will be charged in solution (i.e., the pH is outside the drug's pH range). As the pH naturally neutralizes within the liposome (protons can pass through some membranes), the drug will also be neutralized, allowing it to freely pass through a membrane. These liposomes work to deliver drug by diffusion rather than by direct cell fusion. Altogen Labs • 11200 Manchaca Road • Suite 203 • Austin • TX • 78748 • USA [email protected] • (512) 433-6177 Services > Liposome Encapsulation Evolution of Liposome First generation: Conventional Liposomes Various types of drugs can be loaded into the interior, in the bilayer or at the interface depending on the nature of the compounds. Second generation: PEGylated Liposome It offers significant advantages over conventional liposomes such as prolonged blood circulation time and hence enhanced drug accumulation at the disease site. Other potential benefits include reduced toxicity, reduced dosing, frequency etc. Services > Liposome Encapsulation Evolution of Liposome Third generation: Ligand-Targeted Liposome This is the most advanced liposome system. PEGylated liposomes with targeting ligands (antibodies, antibody fragments, peptides and small molecules) have the potential of specific targeted delivery to the disease site through ligand-receptor binding Lipid-Nanoparticles (Liposphere) Liposphere is a nano-particle with an lipophilic core (such as triglycerides) coated with a monolayer of lipids. Lipophilic drugs are loaded in the oil core. Services > Liposome Encapsulation Factors that affect liposome preparation method The physicochemical characteristics of the material encapsulated and those of the liposomal ingredients The nature of the medium in which the lipid vesicles are dispersed The effective concentration of the entrapped substance and its potential toxicity Optimum size, polydispersity and shelf-life of the vesicles for the intended application Batch-to-batch reproducibility and possibility of large-scale production of safe and efficient liposomal products Additional processes involved during application/delivery of the vesicles Altogen Labs • 11200 Manchaca Road • Suite 203 • Austin • TX • 78748 • USA [email protected] • (512) 433-6177 Services > Liposome Encapsulation Methods of Liposome Preparation Ether/alcohol injection Freeze dry evaporation method Extrusion method Reverse phase evaporation Microfluidization (Microfluidics) Detergent depletion Supercritical fluid injection and decompression Dense gas techniques Dual asymmetric centrifugation High-pressure homogenization Altogen Labs • 11200 Manchaca Road • Suite 203 • Austin • TX • 78748 • USA [email protected] • (512) 433-6177 Services > Liposome Encapsulation Protocols: Freeze-dry Freeze-drying of liposomes can prevent hydrolysis of phospholipids and also help to stabilize encapsulated material. Services > Liposome Encapsulation Protocols: Extrusion Liposome extrusion is a widely used method in which liposomes are forced under pressure through filters with defined pore sizes in order to generate a homogenous population of smaller defined vesicles. Prior to extrusion through the final pore size, multilamellar lipsome (LMV) suspensions are disrupted either by several freeze-thaw cycles or by prefiltering the suspension through a larger pore size (typically 0.2µm1.0µm). This method helps prevent the membranes from fouling and improves the homogeneity of the size distribution of the final suspension. Extrusion through filters with 100nm pores typically yields large, unilamellar vesicles (LUV) with a mean diameter of 120-140nm. Mean particle size also depends on lipid composition and is quite reproducible from batch to batch. Altogen Labs • 11200 Manchaca Road • Suite 203 • Austin • TX • 78748 • USA [email protected] • (512) 433-6177 Services > Liposome Encapsulation Protocols: Microfluidization A major challenge in the development of liposomes for drug delivery is the control of size and size distribution. Microfluidics is an emerging technology for liposome synthesis, because it enables precise control of the lipid hydration process and allows for the production of liposomes ranging from tens of nanometers to tens of micrometers in diameter. Isopropyl alcohol (IPA) containing the dissolved lipids flows through the center inlet channel, and an aqueous solution flows through the two side inlet channels. The stream of lipids in IPA is hydrodynamically focused by two aqueous streams at the cross junction of the microfluidic chip. The liposome formation is based on a diffusion-driven process in which the dissolved lipids self-assemble into liposomes as IPA quickly diffuses and dilutes into two aqueous streams at the interfacial region. The lipid IPA solution is injected into the center channel of the microfluidics network, while phosphate-buffered saline (PBS) is injected into two side channels intersecting with the center channel. Relatively high liposome concentration can be produced at the center point in the channel once the focused IPA stream is diluted to the critical concentration for formation of the more stable liposomes along the interfacial region. Services > Liposome Encapsulation Protocols: DNA plasmid encapsulation Chloroform solutions of lipids (10–20 mg/ml) are mixed in a 12×75 mm2 glass tube at the following composition (20 μmol total lipid, mole percent): Cholesterol 55%, DSPC 20%, DDAB 15% and DSPE-PEG2000 10%. The solvent is evaporated under vortexing and under a thin nitrogen gas stream allowing a thin, fairly even lipid film to form on approximately 6 cm of the glass surface. High vacuum is applied overnight to ensure complete solvent evaporation. A Tris–HCl buffer (300 μl, 50 mM, pH 7.0) is used to hydrate the lipids and allow for vesicle formation. The tube is rotated and lipids allowed to hydrate overnight at room temperature. The next day the liposome preparation is placed in a basket and sonicated for 2 min using a Bransonic water bath. Plasmid DNA (Endo-free) is added to the tube and after collecting the material at the bottom of the tube by a brief spin exactly one volume of 80% ethanol in Tris-buffer (50 mM, pH 7.0) is added dropwise and with mixing during one minute. The tube is subjected to five cycles of freeze-thaw between dry ice/EtOH and 37 °C water bath with 2–3 min in each step. Liposomes are downsized using 11 passes in a hand-held, small-scale extruder with polycarbonate nucleopore filters (400 nm, 200 nm and 100 nm). For each step a small volume of buffer to wash the extruder ensures a complete liposome recovery. The entire SPLP volume (typically 1 ml) after the extrusion process is transferred to a dialysis cassette (10 kDa MWCO) and dialyzed against 0.5 l HEPES buffer (pH 7.4) overnight at room temperature with one buffer exchange. Services > Liposome Encapsulation Protocols: Protein encapsulation Preparation of liposomes Liposomes are prepared by an ethanol injection method. Briefly, varied molar ratios of DSPC/cholesterol/DSPE-PEG/DHA are melted in a 60°C water bath, and the lipid mixture is then dissolved in the proper alcohol solvent and rapidly injected at room temperature with a one-way, 1 mL syringe into a dispersant water solution. The dispersion is extruded ten times through a polycarbonate membrane (100 nm pore size) using an extruder. The various ratios of lipid content/ethanol/water (L/E/W) are evaluated. Preparation of lipoparticles Solid cores are prepared using a physical mix method. Briefly, FITC-BSA and protamine sulfate are freshly dissolved in ethanol. The weight ratio of protamine sulfate/FITC-BSA (20/1) solution is added and mixed. An FITC-BSA/protamine sulfate core is dissolved in the alcohol lipid solution; the correct aliquot of this solution is injected as in the liposome preparation process described above. Untrapped FITC-BSA and protamine sulfate from the lipoparticles is removed by ultracentrifugation at 25,000 g for 15 minutes and further dialyzed against 800 mL distilled water for 12 hours at 4°C to remove untrapped FITC-BSA from the lipoparticle vesicles. Provider of Global Contract Research Services Accelerating Preclinical Research, Drug Discovery & Therapeutics Endpoints Altogen Labs offers encapsulation of any charged molecuIe such as mRNA, siRNA, shRNA, microRNA, plasmid DNA, protein The encapsulated molecule can be transformed into either one of several standard liposome formulations such as PC : Cholesterol and DSPC : Cationic Lipid : PEGylated Lipoid : Cholesterol or a custom liposome formulation Standard formulations including all of the formulations listed in previous table Custom formulation Developing formulation methods Encapsulation of the compound of interest into liposomal formulation This can be done for in vitro or in vivo studies Altogen Labs • 11200 Manchaca Road • Suite 203 • Austin • TX • 78748 • USA [email protected] • (512) 433-6177